[
    {
        "id": 2990,
        "drug_name": "XGEVA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple Myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-01-05",
        "link": "http:\/\/wwwext.amgen.com\/media\/news-releases\/2018\/01\/fda-approves-xgeva-denosumab-for-the-prevention-of-skeletalrelated-events-in-patients-with-multiple-myeloma\/",
        "note": "sBLA approval announced January 5, 2017.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2973,
        "drug_name": "LYNPARZA (olaparib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-01-12",
        "link": "http:\/\/investors.merck.com\/news\/press-release-details\/2018\/US-FDA-Approves-LYNPARZA-olaparib-in-Germline-BRCA-Mutated-Metastatic-Breast-Cancer\/default.aspx",
        "note": "Approval announced January 12, 2018.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2973,
        "drug_name": "LYNPARZA (olaparib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-01-12",
        "link": "http:\/\/investors.merck.com\/news\/press-release-details\/2018\/US-FDA-Approves-LYNPARZA-olaparib-in-Germline-BRCA-Mutated-Metastatic-Breast-Cancer\/default.aspx",
        "note": "Approval announced January 12, 2018.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4610,
        "drug_name": "TRISENOX (arsenic trioxide)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Acute Promyelocytic Leukemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-01-15",
        "link": "http:\/\/www.tevapharm.com\/research_development\/rd_focus\/pipeline\/",
        "note": "Approved January 15, 2018.",
        "company_entity_id": 390,
        "company_ticker": "TEVA",
        "company_name": "Teva Pharmaceutical Industries Limited American Depositary Shares",
        "company_price": "13.4900",
        "company_change": 0.14,
        "company_percent_change": 1.05,
        "company_optionable": 1,
        "company_number_of_shares": 1121094011,
        "price_change_sparkline": [
            [
                12.1,
                1706677200
            ],
            [
                12.46,
                1706763600
            ],
            [
                12.28,
                1706850000
            ],
            [
                12.38,
                1707109200
            ],
            [
                12.25,
                1707195600
            ],
            [
                12.14,
                1707282000
            ],
            [
                12.09,
                1707368400
            ],
            [
                12.01,
                1707454800
            ],
            [
                12.91,
                1707714000
            ],
            [
                12.92,
                1707800400
            ],
            [
                13.17,
                1707886800
            ],
            [
                13.2,
                1707973200
            ],
            [
                13.02,
                1708059600
            ],
            [
                13.07,
                1708405200
            ],
            [
                13,
                1708491600
            ],
            [
                13.05,
                1708578000
            ],
            [
                12.89,
                1708664400
            ],
            [
                13.29,
                1708923600
            ],
            [
                13.3,
                1709010000
            ],
            [
                13.09,
                1709096400
            ],
            [
                13.15,
                1709182800
            ],
            [
                13.5,
                1709269200
            ],
            [
                13.44,
                1709528400
            ],
            [
                13.54,
                1709614800
            ],
            [
                13.53,
                1709701200
            ],
            [
                13.71,
                1709787600
            ],
            [
                13.62,
                1709874000
            ],
            [
                13.35,
                1710129600
            ],
            [
                13.49,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2992,
        "drug_name": "KYPROLIS - (ENDEAVOR)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsed Multiple Myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-01-17",
        "link": "https:\/\/www.amgen.com\/en-au\/media\/news-releases\/2018\/01\/fda-approves-addition-of-overall-survival-data-to-kyprolis-carfilzomib-label\/",
        "note": "sNDA approved January 17, 2018.",
        "company_entity_id": 627,
        "company_ticker": "LGND",
        "company_name": "Ligand Pharmaceuticals Incorporated",
        "company_price": "72.3600",
        "company_change": 0.11,
        "company_percent_change": 0.15,
        "company_optionable": 1,
        "company_number_of_shares": 17705287,
        "price_change_sparkline": [
            [
                73.1,
                1706677200
            ],
            [
                74.17,
                1706763600
            ],
            [
                74.54,
                1706850000
            ],
            [
                74.72,
                1707109200
            ],
            [
                75.31,
                1707195600
            ],
            [
                74.51,
                1707282000
            ],
            [
                75.41,
                1707368400
            ],
            [
                75.88,
                1707454800
            ],
            [
                75.64,
                1707714000
            ],
            [
                71,
                1707800400
            ],
            [
                73.62,
                1707886800
            ],
            [
                74.65,
                1707973200
            ],
            [
                73.66,
                1708059600
            ],
            [
                72.37,
                1708405200
            ],
            [
                72.67,
                1708491600
            ],
            [
                73.56,
                1708578000
            ],
            [
                75.87,
                1708664400
            ],
            [
                74.42,
                1708923600
            ],
            [
                89.2,
                1709010000
            ],
            [
                84.35,
                1709096400
            ],
            [
                79.35,
                1709182800
            ],
            [
                78.7,
                1709269200
            ],
            [
                76.28,
                1709528400
            ],
            [
                74,
                1709614800
            ],
            [
                72.71,
                1709701200
            ],
            [
                72.47,
                1709787600
            ],
            [
                73.77,
                1709874000
            ],
            [
                72.25,
                1710129600
            ],
            [
                72.36,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2992,
        "drug_name": "KYPROLIS - (ENDEAVOR)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsed Multiple Myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-01-17",
        "link": "https:\/\/www.amgen.com\/en-au\/media\/news-releases\/2018\/01\/fda-approves-addition-of-overall-survival-data-to-kyprolis-carfilzomib-label\/",
        "note": "sNDA approved January 17, 2018.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3348,
        "drug_name": "LUTATHERA (lutetium Lu 177)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Inoperable progressive midgut NETs",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-01-26",
        "link": "http:\/\/investorrelations.adacap.com\/phoenix.zhtml?c=253874&p=irol-newsArticle&ID=2328710",
        "note": "Approved January 26, 2018. Acquired from Advanced Accelerator Applications (NASDAQ: AAAP).",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4398,
        "drug_name": "ZYTIGA (abiraterone acetate) - LATITUDE",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "metastatic hormone-na\u00efve prostate cancer (mHNPC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-02-08",
        "link": "https:\/\/www.jnj.com\/media-center\/press-releases\/zytiga-abiraterone-acetate-plus-prednisone-approved-for-treatment-of-earlier-form-of-metastatic-prostate-cancer",
        "note": "sNDA approval announced February 8, 2018.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4501,
        "drug_name": "COSENTYX (secukinumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Psoriasis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-02-08",
        "link": "https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-fda-approval-cosentyxr-label-update-include-moderate-severe-scalp-psoriasis",
        "note": "FDA approval announced February 8, 2018.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2336,
        "drug_name": "ERLEADA (apalutamide)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Non-metastatic castration-resistant prostate cancer (CRPC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-02-14",
        "link": "https:\/\/www.jnj.com\/media-center\/press-releases\/erleada-apalutamide-a-next-generation-androgen-receptor-inhibitor-granted-us-fda-approval-for-the-treatment-of-patients-with-non-metastatic-castration-resistant-prostate-cancer",
        "note": "Approval announced February 14, 2018.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3610,
        "drug_name": "APADAZ (benzhydrocodone and acetaminophen)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Acute pain",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-02-23",
        "link": "http:\/\/investors.kempharm.com\/news-releases\/news-release-details\/kempharm-announces-fda-approval-apadaztm-benzhydrocodone-and",
        "note": "CRL issued June 13, 2016. Resubmitted, and issued FDA Approval February 23, 2018.",
        "company_entity_id": 2030,
        "company_ticker": "ZVRA",
        "company_name": "Zevra Therapeutics Inc.",
        "company_price": "6.2400",
        "company_change": 0.11,
        "company_percent_change": 1.79,
        "company_optionable": 1,
        "company_number_of_shares": 36218164,
        "price_change_sparkline": [
            [
                5.79,
                1706677200
            ],
            [
                5.96,
                1706763600
            ],
            [
                5.78,
                1706850000
            ],
            [
                5.77,
                1707109200
            ],
            [
                5.905,
                1707195600
            ],
            [
                5.81,
                1707282000
            ],
            [
                5.95,
                1707368400
            ],
            [
                6.15,
                1707454800
            ],
            [
                6.11,
                1707714000
            ],
            [
                5.76,
                1707800400
            ],
            [
                6.14,
                1707886800
            ],
            [
                6.68,
                1707973200
            ],
            [
                6.86,
                1708059600
            ],
            [
                6.89,
                1708405200
            ],
            [
                6.78,
                1708491600
            ],
            [
                6.8,
                1708578000
            ],
            [
                6.63,
                1708664400
            ],
            [
                6.87,
                1708923600
            ],
            [
                6.95,
                1709010000
            ],
            [
                6.86,
                1709096400
            ],
            [
                6.74,
                1709182800
            ],
            [
                7.08,
                1709269200
            ],
            [
                6.22,
                1709528400
            ],
            [
                5.91,
                1709614800
            ],
            [
                6.25,
                1709701200
            ],
            [
                6.31,
                1709787600
            ],
            [
                6.1,
                1709874000
            ],
            [
                6.13,
                1710129600
            ],
            [
                6.24,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2402,
        "drug_name": "ZTlido (lidocaine patch 1.8%)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Pain associated with post-herpetic neuralgia (PHN)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-02-28",
        "link": "http:\/\/investors.sorrentotherapeutics.com\/news-releases\/news-release-details\/sorrento-therapeutics-subsidiary-scilex-receives-us-fda-approval",
        "note": "Approval announced February 28, 2018.",
        "company_entity_id": 284,
        "company_ticker": "SRNE",
        "company_name": "Sorrento Therapeutics Inc.",
        "company_price": "0.3073",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 547880267,
        "price_change_sparkline": [
            [
                0.0425,
                1706677200
            ],
            [
                0.054,
                1706763600
            ],
            [
                0.021,
                1706850000
            ],
            [
                0.021,
                1707109200
            ],
            [
                0.02,
                1707195600
            ],
            [
                0.0375,
                1707282000
            ],
            [
                0.0225,
                1707368400
            ],
            [
                0.025,
                1707454800
            ],
            [
                0.025,
                1707714000
            ],
            [
                0.025,
                1707800400
            ],
            [
                0.02,
                1707886800
            ],
            [
                0.048,
                1707973200
            ],
            [
                0.028,
                1708059600
            ],
            [
                0.031,
                1708405200
            ],
            [
                0.025,
                1708491600
            ],
            [
                0.0375,
                1708578000
            ],
            [
                0.099,
                1708664400
            ],
            [
                0.028,
                1708923600
            ],
            [
                0.0267,
                1709010000
            ],
            [
                0.027,
                1709096400
            ],
            [
                0.027,
                1709182800
            ],
            [
                0.02,
                1709269200
            ],
            [
                0.02,
                1709528400
            ],
            [
                0.015,
                1709614800
            ],
            [
                0.026,
                1709701200
            ],
            [
                0.02125,
                1709787600
            ],
            [
                0.021,
                1709874000
            ],
            [
                0.01,
                1710129600
            ]
        ],
        "statuses": []
    },
    {
        "id": 2869,
        "drug_name": "VERZENIO (Abemaciclib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-03-26",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/lilly-receives-additional-fda-approval-for-verzeniotm-abemaciclib-as-initial-treatment-for-advanced-breast-cancer-300604409.html",
        "note": "Approval announced February 26, 2018.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3778,
        "drug_name": "ADCETRIS (brentuximab vedotin)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Frontline Hodgkin lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-04-04",
        "link": "http:\/\/investor.seagen.com\/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2338996",
        "note": "sBLA approval announced March 20, 2018.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3778,
        "drug_name": "ADCETRIS (brentuximab vedotin)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Frontline Hodgkin lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-04-04",
        "link": "http:\/\/investor.seagen.com\/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2338996",
        "note": "sBLA approval announced March 20, 2018.",
        "company_entity_id": 751,
        "company_ticker": "TAK",
        "company_name": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1\/2 of a share of)",
        "company_price": "14.3700",
        "company_change": -0.19999999999999996,
        "company_percent_change": -1.37,
        "company_optionable": 1,
        "company_number_of_shares": 3137776702,
        "price_change_sparkline": [
            [
                14.6,
                1706677200
            ],
            [
                14.38,
                1706763600
            ],
            [
                14.28,
                1706850000
            ],
            [
                13.92,
                1707109200
            ],
            [
                14.16,
                1707195600
            ],
            [
                14.18,
                1707282000
            ],
            [
                14,
                1707368400
            ],
            [
                14.24,
                1707454800
            ],
            [
                14.31,
                1707714000
            ],
            [
                14.34,
                1707800400
            ],
            [
                14.54,
                1707886800
            ],
            [
                14.42,
                1707973200
            ],
            [
                14.62,
                1708059600
            ],
            [
                14.82,
                1708405200
            ],
            [
                14.74,
                1708491600
            ],
            [
                14.64,
                1708578000
            ],
            [
                14.62,
                1708664400
            ],
            [
                14.81,
                1708923600
            ],
            [
                14.84,
                1709010000
            ],
            [
                14.65,
                1709096400
            ],
            [
                14.59,
                1709182800
            ],
            [
                14.56,
                1709269200
            ],
            [
                14.48,
                1709528400
            ],
            [
                14.4,
                1709614800
            ],
            [
                14.69,
                1709701200
            ],
            [
                14.86,
                1709787600
            ],
            [
                14.77,
                1709874000
            ],
            [
                14.57,
                1710129600
            ],
            [
                14.37,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2457,
        "drug_name": "OPDIVO (nivolumab) -  4 week applications",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-04-04",
        "link": "https:\/\/news.bms.com\/press-release\/corporatefinancial-news\/bristol-myers-squibbs-opdivo-nivolumab-now-first-and-only-fda-",
        "note": "Approval announced March 6, 2018.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3232,
        "drug_name": "RUBRACA (rucaparib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Ovarian cancer patients with a BRCA-like mutation",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-04-06",
        "link": "http:\/\/ir.clovisoncology.com\/phoenix.zhtml?c=247187&p=irol-newsArticle&ID=2341439",
        "note": "Approval announced April 6, 2018.",
        "company_entity_id": 93,
        "company_ticker": "CLVS",
        "company_name": "Clovis Oncology Inc.",
        "company_price": "0.0812",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 144955263,
        "statuses": []
    },
    {
        "id": 3714,
        "drug_name": "EXPAREL",
        "clinical_trial_id": "NCT03485014",
        "has_trial_insight_page": 0,
        "indication": "Post surgical pain",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-04-06",
        "link": "http:\/\/investor.pacira.com\/phoenix.zhtml?c=220759&p=irol-newsArticle&ID=2341466",
        "note": "Approval announced April 6, 2018.",
        "company_entity_id": 239,
        "company_ticker": "PCRX",
        "company_name": "Pacira BioSciences Inc.",
        "company_price": "30.5600",
        "company_change": -0.45999999999999996,
        "company_percent_change": -1.48,
        "company_optionable": 1,
        "company_number_of_shares": 46500778,
        "price_change_sparkline": [
            [
                32.59,
                1706677200
            ],
            [
                31.775,
                1706763600
            ],
            [
                30.34,
                1706850000
            ],
            [
                31.14,
                1707109200
            ],
            [
                30.78,
                1707195600
            ],
            [
                28.49,
                1707282000
            ],
            [
                27.7,
                1707368400
            ],
            [
                28.78,
                1707454800
            ],
            [
                30.02,
                1707714000
            ],
            [
                29.21,
                1707800400
            ],
            [
                29.23,
                1707886800
            ],
            [
                29.66,
                1707973200
            ],
            [
                29.08,
                1708059600
            ],
            [
                29.86,
                1708405200
            ],
            [
                29.7,
                1708491600
            ],
            [
                29.97,
                1708578000
            ],
            [
                30.04,
                1708664400
            ],
            [
                29.74,
                1708923600
            ],
            [
                29.85,
                1709010000
            ],
            [
                29.91,
                1709096400
            ],
            [
                29.72,
                1709182800
            ],
            [
                28.86,
                1709269200
            ],
            [
                29.2,
                1709528400
            ],
            [
                29.44,
                1709614800
            ],
            [
                30.11,
                1709701200
            ],
            [
                30.64,
                1709787600
            ],
            [
                31.41,
                1709874000
            ],
            [
                31.02,
                1710129600
            ],
            [
                30.56,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3991,
        "drug_name": "TAVALISSE (Fostamatinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Immune Thrombocytopenic Purpura (ITP)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-04-17",
        "link": "https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=report.page",
        "note": "Approved April 17, 2018.",
        "company_entity_id": 264,
        "company_ticker": "RIGL",
        "company_name": "Rigel Pharmaceuticals Inc.",
        "company_price": "1.4900",
        "company_change": -0.020000000000000018,
        "company_percent_change": -1.3199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 175377812,
        "price_change_sparkline": [
            [
                1.17,
                1706677200
            ],
            [
                1.2,
                1706763600
            ],
            [
                1.14,
                1706850000
            ],
            [
                1.17,
                1707109200
            ],
            [
                1.22,
                1707195600
            ],
            [
                1.12,
                1707282000
            ],
            [
                1.14,
                1707368400
            ],
            [
                1.2,
                1707454800
            ],
            [
                1.21,
                1707714000
            ],
            [
                1.12,
                1707800400
            ],
            [
                1.18,
                1707886800
            ],
            [
                1.22,
                1707973200
            ],
            [
                1.17,
                1708059600
            ],
            [
                1.14,
                1708405200
            ],
            [
                1.12,
                1708491600
            ],
            [
                1.3,
                1708578000
            ],
            [
                1.32,
                1708664400
            ],
            [
                1.42,
                1708923600
            ],
            [
                1.5,
                1709010000
            ],
            [
                1.55,
                1709096400
            ],
            [
                1.52,
                1709182800
            ],
            [
                1.55,
                1709269200
            ],
            [
                1.47,
                1709528400
            ],
            [
                1.48,
                1709614800
            ],
            [
                1.56,
                1709701200
            ],
            [
                1.53,
                1709787600
            ],
            [
                1.57,
                1709874000
            ],
            [
                1.51,
                1710129600
            ],
            [
                1.49,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3747,
        "drug_name": "CRYSVITA (burosumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "X-Linked Hypophosphatemia (XLH) ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-04-17",
        "link": "http:\/\/ir.ultragenyx.com\/news-releases\/news-release-details\/ultragenyx-and-kyowa-kirin-announce-fda-approval-crysvitar",
        "note": "Approval announced April 17, 2018.",
        "company_entity_id": 258,
        "company_ticker": "RARE",
        "company_name": "Ultragenyx Pharmaceutical Inc.",
        "company_price": "47.6600",
        "company_change": -0.85,
        "company_percent_change": -1.75,
        "company_optionable": 1,
        "company_number_of_shares": 82335687,
        "price_change_sparkline": [
            [
                44.11,
                1706677200
            ],
            [
                44.1,
                1706763600
            ],
            [
                43.02,
                1706850000
            ],
            [
                44.76,
                1707109200
            ],
            [
                45.89,
                1707195600
            ],
            [
                44.71,
                1707282000
            ],
            [
                45.45,
                1707368400
            ],
            [
                46.73,
                1707454800
            ],
            [
                46.74,
                1707714000
            ],
            [
                43.98,
                1707800400
            ],
            [
                45.66,
                1707886800
            ],
            [
                46.26,
                1707973200
            ],
            [
                48.92,
                1708059600
            ],
            [
                47.87,
                1708405200
            ],
            [
                48.18,
                1708491600
            ],
            [
                48.88,
                1708578000
            ],
            [
                49.48,
                1708664400
            ],
            [
                50.25,
                1708923600
            ],
            [
                53.66,
                1709010000
            ],
            [
                52.75,
                1709096400
            ],
            [
                51.72,
                1709182800
            ],
            [
                53.69,
                1709269200
            ],
            [
                53.31,
                1709528400
            ],
            [
                51.47,
                1709614800
            ],
            [
                51.26,
                1709701200
            ],
            [
                50.85,
                1709787600
            ],
            [
                50.53,
                1709874000
            ],
            [
                48.51,
                1710129600
            ],
            [
                47.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2231,
        "drug_name": "TAFINLAR (dabrafenib) + MEKINIST (trametinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Melanoma with BRAF V600E or V600K mutations",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-04-30",
        "link": "https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-fda-approval-tafinlarr-mekinistr-adjuvant-treatment-braf-v600-mutant-melanoma",
        "note": "Approval announced April 30, 2018.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2514,
        "drug_name": "KYMRIAH (tisagenlecleucel)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-05-01",
        "link": "https:\/\/globenewswire.com\/news-release\/2018\/05\/01\/1494437\/0\/en\/Kymriah-tisagenlecleucel-first-in-class-CAR-T-therapy-from-Novartis-receives-second-FDA-approval-to-treat-appropriate-r-r-patients-with-large-B-cell-lymphoma.html",
        "note": "Approval announced May 1, 2018.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 1963,
        "drug_name": "PLENVU (NER1006)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Bowel cleansing",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-05-07",
        "link": "http:\/\/ir.valeant.com\/news-releases\/2018\/05-07-2018-115934867",
        "note": "Approval announced May 7, 2018.",
        "company_entity_id": 574,
        "company_ticker": "BHC",
        "company_name": "Bausch Health Companies Inc.",
        "company_price": "9.1900",
        "company_change": 0.07,
        "company_percent_change": 0.77,
        "company_optionable": 1,
        "company_number_of_shares": 365411953,
        "price_change_sparkline": [
            [
                7.85,
                1706677200
            ],
            [
                7.98,
                1706763600
            ],
            [
                7.92,
                1706850000
            ],
            [
                7.77,
                1707109200
            ],
            [
                8.13,
                1707195600
            ],
            [
                8.12,
                1707282000
            ],
            [
                8.13,
                1707368400
            ],
            [
                8.21,
                1707454800
            ],
            [
                8.38,
                1707714000
            ],
            [
                8.41,
                1707800400
            ],
            [
                8.43,
                1707886800
            ],
            [
                8.49,
                1707973200
            ],
            [
                8.51,
                1708059600
            ],
            [
                8.6,
                1708405200
            ],
            [
                8.67,
                1708491600
            ],
            [
                9.3,
                1708578000
            ],
            [
                9.18,
                1708664400
            ],
            [
                8.99,
                1708923600
            ],
            [
                9.18,
                1709010000
            ],
            [
                9.2,
                1709096400
            ],
            [
                9.39,
                1709182800
            ],
            [
                9.89,
                1709269200
            ],
            [
                9.58,
                1709528400
            ],
            [
                9.56,
                1709614800
            ],
            [
                9.23,
                1709701200
            ],
            [
                9.28,
                1709787600
            ],
            [
                9.23,
                1709874000
            ],
            [
                9.12,
                1710129600
            ],
            [
                9.19,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2877,
        "drug_name": "DARZALEX (Daratumumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Frontline multiple myeloma (non-transplant)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-05-07",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/janssen-announces-darzalex-daratumumab-us-fda-approval-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible-300644142.html",
        "note": "Approval announced May 7, 2018.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    }
]